Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 11/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29274283 | 1.00 | CHRM2 (0.40) | CHRM2NR1H2NR1H3SLC6A9CHRM1 | |
| SCHEMBL24675569 | 0.85 | HDAC8 (0.43) | NR1H2NR1H3 | |
| SCHEMBL26959278 | 0.85 | HDAC8 (0.43) | NR1H2NR1H3 | |
| SCHEMBL24763592 | 0.85 | HDAC8 (0.43) | NR1H2NR1H3 | |
| SCHEMBL28966528 | 0.83 | SMO (0.43) | CHRM2NR1H2NR1H3CHRM1CHRM5 | |
| SCHEMBL20141053 | 0.80 | SLC6A7 (0.40) | — | |
| SCHEMBL29088965 | 0.80 | LCAT (0.35) | CXCR3 | |
| SCHEMBL26915045 | 0.80 | MDM2 (0.36) | CHRM2CXCR3 | |
| SCHEMBL26914983 | 0.80 | LCAT (0.35) | CXCR3 | |
| SCHEMBL26914936 | 0.80 | MDM2 (0.36) | CHRM2CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 | CHRM2 4654/4885NR1H2 984/4885NR1H3 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.